Business Wire

HANSHOW

Share
Hanshow Leads Retail Innovation with IoT and GenAI at NRF APAC 2024

Hanshow, a global leader in Electronic Shelf Labels (ESL) and digital retail solutions, proudly participated in the first NRF Big Show 2024 Asia Pacific, held in Singapore from June 11-13. Organized by the National Retail Federation (NRF), this highly anticipated event marked a significant milestone in the retail industry, bringing together the best and brightest minds from around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612653287/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hanshow at NRF APAC 2024 (Photo: Business Wire)

A Leap Forward in Shopper Experience and Store Operation

At this prestigious event, Hanshow introduced its Smart Cart Solution, developed with Microsoft on the Azure Open AI platform, leveraging Generative AI (GenAI) to enhance customer experience and store operations in a smarter, more connected retail ecosystem. This solution featured an AI copilot for personalized shopping, offering tailored recommendations and syncing online and in-store customer profiles for a seamless shopping experience.

Additionally, the Smart Cart enables skip-the-line checkout for faster, more convenient transactions. Retailers benefited from retail media revenue by displaying location-based advertisements and offering smart product recommendations, boosting their revenue. The solution also provided valuable data on shopper behavior and product performance.

In addition, Hanshow’s Lumina digital display series revolutionizes in-store marketing by integrating with GenAI, providing a state-of-the-art digital marketing solution. With the power of GPT-4 and DALL-E3, users can effortlessly craft product POP posters, atmospheric marketing visuals, and persuasive product copy through simple text commands.

"Our co-innovated solutions with Microsoft, showcased at this NRF, mark a significant step in revolutionizing the retail experience," said Shiguo Hou, CEO of Hanshow. "Together, we are not only redefining shopping but also empowering retailers with the tools to excel in a competitive landscape and forge a shared vision for the future. We’re honored to have jointly held our Retail Conference with Microsoft in Singapore, and our meeting with Microsoft APAC CEO Ahmed Mazhari discussed yielded new areas for possible future cooperation."

Sustainability and Growth Vision

Hanshow's vision for a greener future in retail outlines the steps businesses must take to balance decarbonization and sustainability with creating value for customers, employees, and stakeholders. A key component of this vision is the electronic shelf label (ESL) solution, which transforms retail operations by enabling dynamic pricing, real-time promotions, and efficient inventory management. ESLs help retailers significantly reduce their carbon footprint by minimizing food waste and enhancing resource efficiency.

Additionally, Hanshow has expanded its offerings with a digital energy solution. Key aspects of this solution include globally integrated local teams, R&D innovation, 24/7 butler service, a one-stop turnkey PV digital energy system, and flexible financing options with PPA resources. These initiatives drive sustainability and business growth by providing tailored PV, charging, and digital energy management systems.

Hanshow’s participation in NRF APAC underscored its commitment to driving innovation in the retail sector and supporting the digital transformation of retailers worldwide. The hands-on experience provided to attendees was a glimpse into a future where our technology is the cornerstone of a more intelligent, efficient, and eco-friendly retail landscape. As we move forward, Hanshow is committed to continuing to lead and support the global retail community in embracing transformative digital solutions that shape a sustainable and prosperous tomorrow.

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240612653287/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye